The world of life and health sciences is witnessing a transformative shift with generative Artificial Intelligence (AI). This technology is not only revolutionizing the way we approach scientific research and laboratory science but is also reshaping the landscape of scientific equipment and instruments.
One of the most notable developments in this field is the debut of QuantHealth's AI-based program, Katina. This Tel Aviv-based startup has developed a platform that uses AI to simulate hundreds of thousands of potential trial protocol combinations. The platform focuses on patient groups, treatment parameters, and different endpoints that factor into the operational and commercial aspects of a trial. This is a significant leap forward in clinical study design, as it leverages real-world data from 350 million patients, large biomedical knowledge-graphs, and trial data. The company's endpoint prediction accuracy stands at an impressive 86% for investigational therapies, demonstrating the potential of AI in enhancing the efficiency and accuracy of clinical trials.
In the realm of medical imaging, AI is stealing the spotlight. At the annual meeting of the Radiological Society of North America, major players in digital imaging like GE HealthCare, Siemens Healthineers, Philips, and Hologic showcased their cutting-edge AI-powered tech. GE HealthCare, for instance, unveiled its MyBreastAI Suite, a collection of software tools for mammography workflows. Siemens Healthineers is pioneering the use of generative AI to combine imaging scans with clinical reports, a development that could revolutionize diagnostic processes. These advancements underscore the potential of AI in improving diagnostic accuracy and patient care.
The pharmaceutical industry is also harnessing the power of AI. Novartis, for example, has invested in AI technology developer Yseop to automate elements of clinical trial report writing. Yseop uses a natural language processing system to speed up clinical study submission processes by analyzing data and automating the production of key documentation. This could significantly expedite drug development efforts, demonstrating the transformative potential of AI in pharmaceutical research.
These developments highlight the growing influence of generative AI in life and health sciences. As AI continues to evolve and mature, we can expect to see even more innovative applications that will revolutionize scientific research, laboratory science, and the development and use of scientific equipment and instruments. The future of life and health sciences is indeed AI-driven and the possibilities are limitless.
Blog sources:
- QuantHealth Debuts AI-Based Program to Simulate Trials at Scale
- Imaging AI at RSNA, Debuts from GE, Siemens, Philips
- Novartis invests in AI firm Yseop for clinical trial writing
- Conversation with GE HealthCare Chief AI Officer Parry Bhatia
- Phenomic signs second deal in two days, Shape expands Roche pact
